Philogen Past Earnings Performance
Past criteria checks 0/6
Philogen has been growing earnings at an average annual rate of 0.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 26.8% per year.
Key information
0.1%
Earnings growth rate
4.1%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 26.8% |
| Return on equity | -6.8% |
| Net Margin | -24.9% |
| Next Earnings Update | 25 Sep 2024 |
Recent past performance updates
Recent updates
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Apr 14
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Mar 31What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
Feb 24Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
Jun 03Revenue & Expenses BreakdownBeta
How Philogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 25 | -6 | 12 | 0 |
| 30 Sep 23 | 27 | -3 | 12 | 0 |
| 30 Jun 23 | 29 | 0 | 12 | 0 |
| 31 Mar 23 | 28 | -3 | 11 | 0 |
| 31 Dec 22 | 27 | -5 | 11 | 0 |
| 30 Sep 22 | 25 | -5 | 10 | 0 |
| 30 Jun 22 | 23 | -5 | 10 | 0 |
| 31 Mar 22 | 14 | -10 | 9 | 0 |
| 31 Dec 21 | 5 | -16 | 9 | 0 |
| 30 Sep 21 | 6 | -14 | 8 | 0 |
| 30 Jun 21 | 6 | -14 | 8 | 0 |
| 31 Mar 21 | 6 | -13 | 8 | 0 |
| 31 Dec 20 | 6 | -13 | 7 | 0 |
| 30 Sep 20 | 8 | -11 | 8 | 0 |
| 31 Dec 19 | 15 | 1 | 7 | 0 |
| 31 Dec 18 | 16 | 4 | 6 | 0 |
| 31 Dec 17 | 14 | 3 | 5 | 0 |
Quality Earnings: PHIL is currently unprofitable.
Growing Profit Margin: PHIL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHIL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.1% per year.
Accelerating Growth: Unable to compare PHIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.8%).
Return on Equity
High ROE: PHIL has a negative Return on Equity (-6.8%), as it is currently unprofitable.